Business Wire

Paracrine Receives FDA Approval to Launch a U.S. Pivotal Trial in Patients With Hand Dysfunction Due to Diffuse Cutaneous Scleroderma

Pivotal trial to support marketing approval of regenerative cells processed with the Celution® System to commence in Q2 2022 SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that the FDA ...
Business Wire

Paracrine Receives Full FDA Approval of Investigational Device Exemption (IDE) to Launch a U.S. Pivotal Trial in Patients With Diabetic Foot Ulcers

SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that the FDA has granted full approval of its Investigational Device Exemption (IDE) to conduct a new pivotal trial titled Adipose Derived ...
GEN

On Point: Paracrine’s Cell Therapy Uses Adipose-Derived Regenerative Cells for Autologous Reimplantation

The most successful drug or cell therapies are often mechanistically simple and work through a single molecule or cell type. But broadly speaking, when we consider more complex diseases—heart disease, ...